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Abstract. Interferon (IFN) is known as a multifunctional
cytokine. The aim of this study was to examine the different
effects of IFN subclass; namely, IFN-α and IFN-ß, on hepato-
cellular carcinoma (HCC) growth especially in conjunction
with angiogenesis that is known to play a pivotal role in the
tumor growth. Furthermore, we also examined whether the
p53 status in the tumor would alter the anti-tumoral effect
of IFN against HCC growth since the p53 status reportedly
affected the therapeutic effect of anti-angiogenic agents
against cancer. When compared with IFN-α, IFN-ß exerted
a more potent inhibitory effect on HCC growth, even after
the tumor was established, along with suppression of neo-
vascularization in the tumor. A single treatment with clinically
comparable low doses of IFN-ß significantly inhibited HCC
growth whereas the same dose of IFN-α did not. IFN-ß also
significantly suppressed the tumor growth both in the p53-
wild and p53-mutant HCC cells. Our in vitro study revealed
that IFN-ß showed a more potent inhibitory effect on the
endothelial cell proliferation than IFN-α as in the in vivo
study. Collectively, IFN may be an alternative anti-angiogenic
agent against HCC since it exerted a significant tumoricidal
effect regardless of the host p53 status even at a low dose.
A cautious approach may be also required in the clinical
practice since even in a same IFN subclass (class-I), IFN-α
and IFN-ß exert tumoricidal effects of different magnitudes
on HCC.
Introduction
Hepatocellular carcinoma (HCC) is now the fifth most common
cancer worldwide, and its incidence will further increase
accounting for 500,000 new cases annually (1). Despite the
available therapeutic options, the incidence is still nearly
equal to the mortality rate. At present, liver transplantation is
considered the only curative option for HCC. However, it is
not feasible to apply this option for all patients with HCC
since the number of donors is absolutely insufficient. Several
other modalities, such as surgery, percutaneous ethanol
injection (PEI), transcatheter arterial embolization (TAE),
and radiofrequency ablation (RFA), are reportedly useful to
improve the prognosis in patients with small HCC (1). For
advanced HCC, chemotherapy is the only remaining option
although its efficacy is very poor so far (2). Recently, the
progress in implantable drug delivery system has allowed
repeated arterial infusion of chemotherapeutic agents, such as
cisplatin (CDDP) and 5-fluouracil (5-FU), for patients with
advanced HCC (3). An alternative agent; namely, interferon
(IFN), has also been reported to improve the survival rate in
combination with 5-FU (4,5). 
IFNs are a family of natural glycoproteins initially dis-
covered on their basis of antiviral activity. These cytokines
have various biological properties, including immuno-
modulation and anti-proliferative actions (6). Type-I IFN,
IFN-α and IFN-ß have been widely used for the treatment of
patients with chronic hepatitis C in the clinical practice (7,8).
There is a growing body of evidence that IFN reduces the
incidence of HCC in patients with chronic hepatitis C and the
intrahepatic recurrence of HCC (9). Furthermore, several
reports demonstrated a drastic HCC regression after IFN
therapy (10). However, to date, few studies have shown
tumoricidal differences between IFN-α and IFN-ß.
Any solid tumor that has not acquired its new own blood
supply can not grow to more than only a few millimeters in
size, including HCC (11). One of the characteristic features
of HCC in the clinical practice is hypervascularity. Several
studies have shown that neovascularization and angiogenic
factors, such as the vascular endothelial cell growth factor
(VEGF), are significantly up-regulated in the human HCC
samples (12,13). We previously reported that angiogenesis
plays a pivotal role in the murine HCC development, and
that suppression of the VEGF-signaling pathway markedly
attenuated the tumor growth (14). IFN also has an anti-
angiogenic activity both in vitro and in vivo (15). Although
IFN-α and IFN-ß reportedly exert different anti-angiogenic
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activities in vitro (16,17), the in vivo anti-angiogenic dif-
ferences in HCC have not been reported yet. 
HCC is molecularly complex, as nearly every carcinogenic
mechanism is altered to some degree, and HCC cells harbor
numerous genetic defects such as p53 (18). Mutations of p53
gene are detectable in ~50% of HCC especially in the late
stage of HCC (19). Loss of the p53 gene function is associated
with poorly differentiated HCC and a shorter survival time
(18). It has been reported that the host p53 status affects
the tumor response to anti-angiogenic therapy, and that
transcription of p53 gene is induced by IFN (20). It is very
important to examine whether the anti-angiogenic therapeutic
effect of IFN is affected by the host tumoral p53 status or not
for future clinical application.
In the present study, to evaluate the feasibility of future
clinical application, we examined the different effects of
IFN-α and IFN-ß at clinically comparable low doses on the
experimental HCC tumor development and angiogenesis.
We also elucidated whether the p53 status in the tumor alters
the anti-tumoral effect of IFN against HCC growth, and
investigated the possible mechanisms involved.
Materials and methods
Compounds and cell lines. IFN-α and IFN-ß were generously
supplied by Hayashibara Biochemical Laboratories, Inc.
(Okayama, Japan) and Toray Industries, Inc. (Tokyo, Japan),
respectively. The p53-wild and -mutant HCC cell lines,
BNL.1 ME A.7R.1 (BNL) and PLC/PRF/5 (PLC) were
obtained from the Japanese Cancer Research Resources Bank
(Tokyo, Japan). The primary human umbilical endothelial
cells (EC) were purchased from Kurabo (Osaka, Japan).
These cells were cultured in the respective recommended
medium as described previously (21).
Animal treatment. A total of 60 male 6-week-old BALB/c
(n=30) and BALB/c-nu/nu (n=30) mice were purchased from
Japan SLC Inc. (Hamamatsu, Shizuoka, Japan). They were
housed under controlled temperature conditions and relative
humidity, with 10-15 air changes per hour (h) and light
illumination for 12 h a day. To compare the tumoricidal
difference between IFN-α and IFN-ß, we transplanted 5x106
PLC cells into the flank of BALB/c-nu/nu mice. The mice
were randomly divided into 4 groups (n=10 in each group).
After the mean tumor volume reached 200 mm3, the mice of
the phosphate buffer saline (PBS)-treated group served as a
control (Cont). The mice in IFN-α group and IFN-ß group
received 1x104 IU of murine IFN-α and -ß, respectively, twice
a week with subcutaneous injection on the contralateral side
of the tumor. The doses of these agents are reportedly almost
comparable to those used in the clinical practice (22). 
The next experiment was conducted to examine the effect
of IFN-ß on BNL tumor growth. In this experiment, adminis-
tration of IFN-ß started on day 0, and IFN treatment was
similar to that of the PLC experiment. The tumor was measured
twice a week as described previously (22), and the animals
were allowed free access to food and water throughout the
acclimation and experiment protocols. The mice were
sacrificed 56 and 32 days after the tumor cell implantation in
the PLC and BNL experiments, respectively. All animal
procedures were performed according to approved protocols
and in accordance with the recommendations for the proper
care and use of laboratory animals.
Neovascularization in the tumor. To evaluate the expression
of CD31 mRNA, which is widely used as neovascularization
marker, we performed a semi-quantitative RT-PCR analysis.
Tumors were immediately snap-frozen for RNA extraction
(n=5 in each experimental group), and mRNA was extracted
from the pool of tumors. The primer for the mouse CD31
was follows: sense, 5'-CGGTGGATGAAGTTGTGATT-3';
anti-sense, 5'-ACCGTCTCTTGTGGCTCTCGT-3'. PCR
was performed at 94˚C for 1 min, at 52˚C for 1 min, and at
72˚C for 1 min for 30 cycles. To prevent genomic DNA
contamination, all RNA samples were subjected to DNase I
digestion and checked by 30 cycles of PCR to confirm the
absence of any amplified DNA. The PCR products (620 bp)
were analyzed by electrophoresis on 1.5% agarose gel, and the
products were visualized by staining with ethidium bromide.
Densitometric analysis was performed by measuring the
absorbance of each band with Fuji BAS 2000 image analyzer
(Fuji Co., Tokyo, Japan). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an internal control.
Apoptosis and VEGF expression in the tumor. Apoptosis was
detected with DNA fragmentation products that were stained
by in situ 3'-end labeling [terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick-labeling (TUNEL)] with paraffin-
embedded sections. In each tumor, the positive cells in 10
high-power fields at a magnification x400 were examined as
described previously (23). For measurement of the VEGF
protein level in the tumor, five tumors having the same size
were chosen from each group, because a different size of
tumor may cause different hypoxic conditions, which strongly
induce VEGF (24). The tumor samples were prepared as
described previously (25). After the protein concentration
was equalized, the VEGF level was measured with an ELISA
kit (R&D Systems, Minneapolis, MN, USA) in accordance
with the supplier's instructions.
In vitro proliferation and assay. The in vitro proliferation was
determined by MTT assay as described elsewhere (25). The
cell proliferation was quantified via conversion of tetrazolium,
3-(4,5-diethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) by cells cultured in 12-well plate. MTT was added
to each well at a final concentration IFN-α and -ß (10, 102,
103 IU/ml). After 4-h incubation at 37˚C with MTT, the
untreated MTT and medium were removed, and 2 ml of
dimethyl sulfoxide were added to solubilize the MTT
formazan. After gentle agitation for 10 min, the optical
density of each well, which is directly proportional to the
number of living cells, was measured with a 540-nm filter.
The absorbance was read with an ELISA plate reader (n=6
per group). 
Statistical analysis. To assess the statistical significance of
inter-group differences in the quantitative data, Bonferroni's
multiple comparison test was performed after One-way
ANOVA. This was followed by Barlett's test to determine the
homology of variance.
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Results
Effects of IFN-α and IFN-ß on HCC growth and neovascu-
larization. We first examined the effects of clinically
comparable doses of IFN-α and -ß on the HCC growth. As
shown in Fig. 1, IFN-ß treatment, even after the tumor was
established, showed a marked inhibitory effect on HCC
development as compared with the control group (p<0.05),
whereas IFN-α treatment did not. We next examined the
effects of IFN-α and -ß on neovascularization in the tumor to
elucidate whether or not the inhibitory effects of these agents
are associated with alteration of angiogenesis. We performed
a semi-quantitative RT-PCR analysis of the CD31 gene
expression to evaluate neovascularization. As shown in
Fig. 2, almost in parallel to the results of the HCC growth,
the expression of CD31 in the IFN-ß treatment group was
markedly suppressed as compared with the control group,
whereas IFN-α treatment did not exert such an inhibitory
effect. Both compounds at the current doses did not affect the
healthy state parameters; e.g., the body weight during the
experiment (data not shown).
Effects of IFN-α and IFN-ß on EC proliferation. To elucidate
whether the differential tumoricidal effect between IFN-α
and -ß via anti-angiogenesis was due to the cytotoxic sensitivity
to the EC or not, we next examined the effects of IFN-α and -ß
on EC proliferation in vitro. Both IFN-α and -ß inhibited the
EC proliferation in a dose-dependent manner. However, the
sensitivity was significantly different. IFN-ß had a marked
inhibitory effect on EC proliferation even at a low dose
(10 IU/ml), whereas IFN-α did not exhibit such an inhibitory
effect even at a ten-times higher dose (100 IU/ml). IFN-α first
exerted a significant inhibitory effect at 1,000 IU/ml although
its magnitude was very low as compared with IFN-ß (Fig. 3).
Neither IFN-α nor IFN-ß suppressed the HCC proliferation
in vitro even at a high dose (1000 IU/ml) (data not shown).
Effect of the host p53 status on the tumoricidal effect of IFN.
We first confirmed the host p53 status of BNL and PLC by
ELISA (Roche, Germany; and Oncogene, Cambridge, MA,
USA), and found that BNL and PLC exerted p53-wild and
mutant status, respectively (data not shown) as described
previously (26). Since only IFN-ß exerted an inhibitory effect
on the HCC growth at the current dose, we employed IFN-ß in
the following study. We then examined whether the tumoricidal
effect of IFN-ß was altered by the host p53 status or not. As
shown in Fig. 4, IFN-ß exerted a marked inhibitory effect on
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Figure 1. Effects of IFN-α and IFN-ß on the HCC growth. A clinically
comparable low dose of IFN-ß, even after the tumor was established,
showed a marked inhibitory effect on HCC development as compared with
the control group, whereas IFN-α treatment did not. The tumor volume was
determined by calipers at the indicated time-points. Each point represents
the mean ± SD (n=10). *Statistically significant difference between the
indicated experimental groups (p<0.05). Cont, PBS-treated control group.
INF-α, IFN-ß, IFN-α and IFN-ß treated groups at dose of 1x104 IU/twice a
week starting from day 14 (the black arrow), respectively. 
Figure 2. Effects of IFN-α and IFN-ß on the mRNA expressions of CD31.
The mRNA expressions were examined by RT-PCR as described in Materials
and methods. IFN-ß showed a significant inhibitory effect on neo-
vascularization in the tumor as compared with the control group almost in
parallel with the suppression of tumor growth, whereas IFN-α treatment did
not. Each bar represents the mean ± SD (n=5). *Statistically significant
difference between the indicated experimental groups (p<0.05). Cont,
PBS-treated control group. INF-α, IFN-ß, IFN-α and IFN-ß treated groups,
respectively. 
Figure 3. Effects of IFN-α and IFN-ß on the EC proliferation in vitro. Cell
proliferation was measured by MTT assay as described in Materials and
methods. Although both IFN-α and IFN-ß inhibited the EC proliferation in
a dose-dependent manner, IFN-ß exerted a more potent inhibitory effect
than IFN-α. Each bar represents the mean ± SD (n=5). * and ** indicate
statistically significant differences between the indicated experimental
groups (p<0.05 and 0.01, respectively). IFN-α and IFN-ß (10, 102, 103):
IFN-α and IFN-ß-treated groups at doses of 10, 102, 103 IU/ml, respectively.
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the HCC growth regardless of the host p53 status; i.e., BNL-
p53-wild and PLC-p53-mutant tumors.
Angiogenesis, apoptosis, and VEGF in the tumor. To elucidate
the possible mechanism of the inhibitory effect of IFN-ß,
we elucidated the neovascularization, apoptosis, and VEGF
expression level in the BNL and PLC tumors. Similar to the
tumoricidal effect, IFN-ß significantly suppressed the intra-
tumoral neovascularization in both the BNL (p53-wild) and
PLC (p53-mutant) tumors almost along with inhibition of the
tumor growth (Fig. 5). On the other hand, the TUNEL-positive
apoptotic cells markedly increased in both the BNL and PLC
tumors by treatment with IFN-ß. The incidence of apoptosis
in the tumor almost corresponded to the effect of tumor
development inhibition (Fig. 6). We also examined the VEGF
protein level in the tumor, and found that the VEGF expression
was significantly attenuated by IFN-ß in both the BNL and
PLC tumor indicating that the anti-angiogenic activity by IFN
was likely, at least partly, to mediate the VEGF inhibition
(Fig. 7). 
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Figure 4. Correlation between the tumoricidal effect of IFN-ß and the host p53 status in the p53-wild (A) and -mutant HCC (B). Since only IFN-ß exerted an
inhibitory effect on the HCC growth at the current dose, we employed IFN-ß in this study. IFN-ß revealed a marked inhibitory effect on the HCC growth
regardless of the host p53 status; i.e., BNL-p53-wild and PLC-p53-mutant tumors. Each point represents the mean ± SD (n=10). *Statistically significant
difference between the indicated experimental groups (p<0.05). Cont, PBS-treated control group. IFN-ß, IFN-ß treated group. 
Figure 5. Effects of IFN-α and IFN-ß on the mRNA expressions of CD31. The mRNA expressions were examined by RT-PCR as described in Materials and
methods. Similar to the tumoricidal effect, IFN-ß significantly suppressed the intra-tumoral neovascularization both in the BNL (A, p53-wild) and PLC (B,
p53-mutant) tumors almost along with inhibition of the tumor growth. Each bar represents the mean ± SD (n=5). *Statistically significant difference between
the indicated experimental groups (p<0.05). Cont, PBS-treated control group. IFN-ß, IFN-ß treated group. 
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Discussion
IFN was originally identified because of its function in anti-
viral host defense, and type-I IFN, IFN-α, and IFN-ß are
widely used for eradication of hepatitis viruses in patients
with chronic hepatitis (8). Recent studies have revealed
that IFN also exerted a tumoricidal effect in several types
of tumors, including HCC (10,27). Most of these studies
showed that the tumoricidal effect of IFN was due to direct
cytotoxicity against the tumor cells at relatively high doses
(28). However, the long-term administration of high doses
of IFN is unacceptable for the patients with chronic liver
diseases. In the clinical practice, continuous administration of
high doses of IFN resulted in several symptoms including
fatigue, anorexia, weight loss, dizziness, and severe hemato-
logical disorders (28).
Since therapies aiming at destruction of the tumor vascu-
lature can achieve rapid regression of the experimental tumors,
the anti-angiogenic therapy has been under investigation
around the world, including the use of gene therapy, anti-
angiogenic recombinant proteins, monoclonal antibodies,
and various drugs (29,30). The first anti-angiogenic agent
approved in the clinical practice was Bevacizumab (Avastin),
a humanized version of the VEGF monoclonal antibody, in
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Figure 6. Effects of IFN-α and IFN-ß on the apoptotic index in HCC. The apoptotic index was elucidated by immunohistochemical analysis as described in
Materials and methods. The TUNEL-positive apoptotic cells markedly increased both in the BNL (A, p53-wild) and PLC (B, p53-mutant) tumors by
treatment with IFN-ß. The incidence of apoptosis in the tumor almost corresponded to the effect of tumor development inhibition. Each bar represents the
mean ± SD (n=5). *Statistically significant difference between the indicated experimental groups (p<0.05). Cont, PBS-treated control group. IFN-ß, IFN-ß
treated group. 
Figure 7. Effects of IFN-α and IFN-ß on the VEGF expression in HCC. The VEGF protein level was measured by ELISA as described in Materials and
methods. IFN-ß significantly suppressed the intra-tumoral VEGF expression both in the BNL (A, p53-wild) and PLC (B, p53-mutant) tumors almost along
with inhibition of the tumor growth, indicating that the anti-angiogenic activity of IFN was likely, at least partly, to mediate the VEGF inhibition. Each bar
represents the mean ± SD (n=5). *Statistically significant difference between the indicated experimental groups (p<0.05). Cont, PBS-treated control group.
IFN-ß, IFN-ß treated group. 
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2004 (31). Bevacizumab exerted a significant beneficial
effect in patients with metastatic colon cancer in combination
with 5-FU-based chemotherapy regimens (32). Sorafinib is
another anti-angiogenic agent which blocks Raf kinase and
VEGFR-2 tyrosine kinase inhibitor (33). Sorafinib has been
recently approved by the Food and Drug Administration in
the United States of America for metastatic renal cell carci-
noma, and it is currently under clinical trials for other organ
malignancies (34). It has been reported that the Raf activity
and VEGFR-2 expression were significantly up-regulated in
the human HCC tumor samples (35). In Japan, a clinical trial
of Sorafinib against the HCC cumulative recurrence after
TAE has recently been launched. However, it appears that
some more time is required before Sorafinib can be applied
widely in the clinical practice for HCC. An alternative
approach may be to find a clinically available compound
that also shows an anti-angiogenic activity until these new
drugs become widely available. In the current study, we
showed that clinically comparable low doses of IFN signi-
ficantly suppressed the HCC growth via anti-angiogenesis.
Although both IFN-α and IFN-ß utilized the same type
receptor, IFN-ß exerted a more potent anti-angiogenic
activity than IFN-α. Several studies have shown that the
signaling cascades of IFN-α and IFN-ß are different in several
types of cells including the HCC cells (36,37). IFN-α and
IFN-ß activated ERK1/2 and or AKT independently of
modulating the proliferation of HCC cells (38). Since the toxic
sensitivities of IFN-α and IFN-ß for the EC were remarkably
different, there may be a possibility that different signaling
cascades were utilized for each IFN in the EC. 
Some recent studies have revealed a close relationship
between the p53 status of the host tumor cells and the sensi-
tivity for anti-angiogenic therapy (20). It has been reported
that mice bearing tumors derived from p53 (-/-) HCT116
human colorectal cancer cells were less responsive to anti-
angiogenic combination therapy than mice bearing isogenic
p53 (+/+) tumors (39,40). The less biological activities of
IFN under the condition of p53 (-/-) for tumor suppression
and antiviral defense have also been reported (20). In this
study, we observed that the anti-angiogenic activity of IFN
was not significantly different regardless of the host p53
status. At this time, the exact reason for this discrepancy is
still obscure. However, it has been reported that inhibition of
p53 during angiogenesis does not affect the extent of new
vessel formation (41). IFN also prevented and delayed rat
hepatocarcinogenesis through p53-independent pathway (42).
Furthermore, it has been recently reported that the p53 status
could not estimate the prognosis of the HCC patients, whereas
angiogenic factors such as VEGF showed a positive correlation
with the prognosis (43,44).
Taken together, there may be a possibility that the anti-
angiogenic activity of IFN is tumor cell type specific. Alter-
natively, the sensitivity of the newly developed EC in HCC
for the anti-angiogenic agents may be independent of the p53
status. Further studies are required to elucidate the exact
mechanism in the future.
Augmentation of apoptosis without affecting the tumor
cell proliferation is known as one of the characteristic features
of the effectiveness with anti-angiogenic therapy (45). We
observed that the significant increase in apoptosis in HCC
by treatment with IFN almost corresponded to the effect of
tumor growth inhibition, and that IFN did not alter the
proliferation of HCC cells in vitro. These results suggested
that IFN induced tumor inhibition by means of increasing
apoptosis in the tumor but not via suppression of the tumor
cell proliferation. It is an important issue to elucidate whether
the low dose of IFN directly induced the tumor cell apoptosis
or not. We observed that, even at a low dose, IFN significantly
inhibited the EC proliferation in vitro, whereas it did not
affect the HCC cell proliferation. Furthermore, IFN attenuated
the expression of VEGF in the tumor, which is known as a
survival factor for the EC (46). Taken together, IFN may first
induce EC apoptosis, with subsequent secondary apoptosis in
the tumor. Alternatively, IFN acts on both HCC cells and EC
by down-regulation of the intra-tumoral VEGF and inhibition
of EC proliferation, respectively. These biphasic effects of
IFN may also play an important role in the tumoricidal effect
against HCC.
In conclusion, IFN exerted a marked inhibitory effect
on the HCC growth, even after the tumor was established,
via anti-angiogenesis along with suppression of VEGF and
augmentation of apoptosis in the tumor. IFN-ß significantly
revealed more potent tumoricidal effect than IFN-α, and a
clinically comparable low dose of IFN-ß inhibited the HCC
growth regardless of the host p53 status. A cautious approach
may be also required in the clinical practice since even in the
same IFN subclass (class-I), IFN-α and IFN-ß exert tumoricidal
effects of different magnitudes on HCC. 
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